albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. (PubMed, Ann Surg Oncol) - "CA19-9 > 500 U/mL serves as an effective indicator for implementing intensive NAC in anatomically resectable pancreatic cancer. This biomarker-based strategy effectively extracts the beneficial group from NAC, prolonging survival outcomes through better systemic disease control."

Journal • Oncology • Pancreatic Cancer • Solid Tumor • CA 19-9

Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: a phase 2 clinical trial. (PubMed, Int J Surg) - P2 | "Neoadjuvant treatment with APC regimen for locally advanced ESCC achieved excellent pCR rates and a well-tolerated safety profile. This combination chemotherapy could serve as one optional neoadjuvant treatment. (ClinicalTrials.gov: NCT04390958)."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Infectious Disease • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Squamous Cell Carcinoma

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer (clinicaltrials.gov) - P2 | N=238 | Not yet recruiting | Sponsor: Henan Cancer Hospital

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • PD-L1

POD1UM-304: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=583 | Active, not recruiting | Sponsor: Incyte Corporation | Trial completion date: Apr 2025 ➔ Jul 2026

Trial completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer (clinicaltrials.gov) - P3 | N=324 | Completed | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Apr 2026 ➔ Mar 2025 | Trial primary completion date: Apr 2024 ➔ Nov 2024 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

SMART: Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - P=N/A | N=27 | Recruiting | Sponsor: University of Saskatchewan | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab (atezo) plus nab-paclitaxel (nPac) therapy for patients (pts) with PD-L1+ advanced triple-negative breast cancer (aTNBC) (ESMO-BC 2025) - P3 | "bPermitted if TFI (except capecitabine) ≥12 months. Safety and efficacy in the global EL1SSAR study were consistent with results from IMpassion130 in a more selected population. Results reinforce the importance of robust PD-L1 assessment to select pts with the best outcomes on atezo."

Clinical • IO biomarker • Late-breaking abstract • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

DESTINY-Breast06 (DB-06) post-hoc analysis by physician's choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC) (ESMO-BC 2025) - P3 | "Here, we report a post-hoc analysis by TPC type. Patients were randomized (1:1) to T-DXd 5.4 mg/kg every 3 weeks or TPC (capecitabine [CAPE], nab-paclitaxel, or paclitaxel). In this analysis, T-DXd showed benefit over all TPC subgroups (including CAPE); these findings support T-DXd as a treatment option in HR+, HER2-low/ultralow mBC with prior ET but no chemotherapy, as previously reported in the ITT population. T-DXd safety outcomes were consistent with those previously reported."

Clinical • Metastases • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial. (PubMed, Cancer Lett) - "The combination of inetetamab and vinorelbine has demonstrated survival benefits with an acceptable toxicity profile in HER2+ metastatic breast cancer (MBC) patients. No death occurred during the neoadjuvant treatment. Neoadjuvant treatment with inetetamab, in combination with pertuzumab and nab-paclitaxel, demonstrates good efficacy and tolerability, especially in ER-negative patients."

Journal • P2 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Infectious Disease • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • ER • HER-2

Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. (PubMed, J Clin Oncol) - P2 | "Although the primary end point was not met and TrAEs were increased by Toc, increased survival at 18 months and reduced muscle wasting support an anticachexia effect of IL-6 blockade independent of GDF15. Further studies could leverage these findings for precision anticachexia therapy."

Journal • P2 data • Cachexia • Oncology • Pancreatic Cancer • Solid Tumor • GDF15

Real World Advances in Metastatic Pancreatic Cancer Treatment in the Pre-Molecular Era: A retrospective single-center analysis 2010 - 2018. (PubMed, Oncol Res Treat) - "In summary, systemic treatment of mPAC intensified during the study period with the availability of new first-line combination chemotherapy options and more lines of therapy. In parallel, patient survival improved, suggesting a causal relationship between more effective chemotherapy and improved outcome. Combination chemotherapy is standard-of-care for mPAC, while the future impact of molecular profiling and precision oncology on real-world patient outcome remains to be determined."

Journal • Real-world evidence • Retrospective data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter) (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

BGB-LC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=400 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: Jul 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

ADAPT-MRD: Adjuvant Pancreatic Therapy Guided by MRD (clinicaltrials.gov) - P=N/A | N=856 | Not yet recruiting | Sponsor: Ruijin Hospital

Circulating tumor DNA • New trial • Oncology • Pancreatic Cancer • Solid Tumor

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

Effects of albumin-bound paclitaxel combined with Sophora subprostrate polysaccharide on inflammatory factors and immune function in breast cancer rats. (PubMed, Discov Oncol) - "Albumin-bound paclitaxel combined with Sophora subprostrate polysaccharide can reduce the local inflammation level, promote the proportion of CDB + T cells and NK cells and cell killing function, reduce the proportion of MDSC and immunosuppressive level, enhance the anti-tumor immune function of tumor-bearing mice, and slow the growth of tumors."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • ARG1 • CD8 • GZMB • IL10 • IL2RA • PRF1 • TNFA

Therapeutic potential of [64Cu]Cu-Labeled Nanoparticle Albumin-Bound Paclitaxel by SPARC-mediated tumor uptake (SNMMI 2025) - "Our findings demonstrate that nab-paclitaxel exhibites SPARC-mediated tumor-specific uptake, leading to significant therapeutic effects in SPARC positive tumors. These results underscore the potential of nab-paclitaxel as a theranostic nanoplatform for cancers with high SPARC expression."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • SPARC

Low-dose Fibronectin-targeted Gd-based contrast agent Enables Early and Accurate Assessment of Chemotherapy Response in Pancreatic Ductal Adenocarcinoma (SNMMI 2025) - "Purpose/Background: Albumin-bound paclitaxel and gemcitabine (AG) chemotherapy is a mainstay in treatment of pancreatic ductal adenocarcinoma (PDAC). This study primarily indicates fibronectin-targeted molecular MRI possesses clinical applications in accurate assessment and prediction of drug resistance to AG chemotherapy, and FMI with targeted probe show promising application in fluorescence-guided surgery."

Fibrosis • Immunology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • EDB-FN

On the importance of the metrics used for assessing dual-tracer 18F-FDG – 68Ga-FAPI PET scans in triple negative breast cancer patients (SNMMI 2025) - P2 | " SKYLINE is an ongoing trial prospectively enrolling 160 pts with TNBC split in 2 cohorts: cohort A consists of pts with stage II-III TNBC treated with neoadjuvant therapy combining tiragolumab, atezolumab and chemotherapy before curative surgery, and cohort B includes pts with de novo or relapsed stage IV TNBC who receive nab-paclitaxel, atezolizumab and tiragolumab until disease progression or unacceptable toxicity. Twenty pts have been enrolled (cohort A: 14, cohort B: 6), with 16 scanned at the 2 time points, yielding 72 analyzed PET scans. In both cohorts at baseline, all primary lesions had elevated FDG and FAPI uptake (mean FDG SUVmax ± 1 sd =18.8±7.5, range [8.6-40.2] ; mean FAPI SUVmax=15.8±4.9, range [7.8-25.6]). In these primary lesions at baseline, FDG SUVmax was greater than FAPI SUVmax in 14 pts (cohort A: 10, cohort B: 4) and smaller in 6 pts (cohort A: 4, cohort B: 2). In cohort A, the mean rSUVmax in the..."

Clinical • IO biomarker • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • TIGIT

Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study (RAMP 205). (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT05669482 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P1/2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Nanoemulsification of PTX and BEZ235 inhibits colon cancer growth. (PubMed, Sci Rep) - "Finally, we found that NEs-PTX-BEZ235 significantly killed colon cancer cells, especially drug-resistant cells, and performed better than Nab-PTX. It may play a synergistic role in reducing drug resistance, inhibiting tumor stemness and inducing apoptosis of colon cancer cells by inhibiting drug resistance proteins."

Journal • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Case Report: Two cases of chemotherapy refractory aggressive variant prostate cancer with extreme durable response to PARP inhibitor. (PubMed, Front Oncol) - "He was treated with docetaxel/albumin-bound paclitaxel and cisplatin in the first line. Second-line therapy was applied with radiotherapy and Olaparib after failure of first-line therapy, resulting in a PSA response sustained for three years...Radiotherapy and Fluzoparib + abiraterone was applied as subsequent treatments with a PSA response for 2 years. These two cases demonstrating a satisfactorily durable response to PARP inhibitors indicating its clinical benefit in AVPC population with detected DNA damage response (DDR) defects. The survival improvement with PARP inhibitors observed in our clinical experiences, along with current advances in tumor sequencing provide more information on future clinical trials and explorations of innovative therapies in AVPC population."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA2 • FANCA • HDAC2 • PTEN • RB1 • TP53

Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health. (PubMed, RSC Adv) - "Nanoparticles such as Abraxane® and engineered ferritin nanocages are at the forefront of cancer treatment, enhancing the precision and effectiveness of chemotherapy while minimizing adverse effects...Addressing these issues through rigorous research and innovation is crucial for integrating PBNPs into mainstream therapeutic practices. PBNPs offer transformative solutions in both antimicrobial and cancer therapies, with significant implications for improving public health outcomes globally."

Journal • Review • Immune Modulation • Immunology • Infectious Disease • Oncology

ANALYSIS OF SURVIVAL AND PERI-OPERATIVE OUTCOMES IN PERIAMPULLARY CARCINOMA/ PANCREATIC DUCTAL ADENOCARCINOMA FOLLOWING NEOADJUVANT CHEMO/RADIATION AND SURGERY VS. UPFRONT SURGERY (SSAT 2025) - "Neoadjuvant therapies included Gemcitabine + Oxaliplatin, Gemcitanine + Nabpaclitaxel, FOLFIRINOX, Gemcitabine + 36GY 15# RT, depending upon the patient fitness and biochemical parameters... Upfront surgery was associated with better R0 resection rates in resectable PDAC cases, giving importance to requirement of earlier detection and better screening protocols. This study also reiterates the need of neoadjuvant treatment in borderline and locally advanced tumours to downstage them, since aggressive tumour biology of PDAC renders majority of cases unresectable."

Clinical • Surgery • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

CHEMOTHERAPY DOSE-INTENSITY AND OUTCOMES IN RESECTED PANCREATIC CANCER (SSAT 2025) - "Introduction: Both FOLFIRINOX and gemcitabine/nab-paclitaxel (GA) are standard therapy for curative intent treatment in pancreatic cancer... Nearly half the patients who receive FOLFIRINOX or GA require dose-reduction over the course of chemotherapy. Of the patients that received >70% of the optimal chemotherapy regimen, 61.5% reduced their regimen at some point in treatment. Survival is related to dose-intensity, but the sample size is not large enough to determine the cutoff for optimal survival."

Oncology • Pancreatic Cancer • Solid Tumor